Respiratory tract infection is any infection in the nose, sinuses around the nose, throat (pharynx), voice box (larynx), and windpipe (trachea), airways (bronchi) or lungs, which may occur anytime, usually beginning with cold. This infection is usually caused by bacteria and viruses. Virus prone respiratory tract infection are easily transmitted and very contagious while bacterial infection can also be developed during the course of an upper respiratory tract infection. Respiratory tract infection is generally divided into two categories- upper respiratory tract infection (infection in nose, throat, and pharynx) and lower respiratory tract infection (infection below the larynx).
Market Dynamics
The global respiratory tract infection market is expected to witness lucrative growth due to factors such as increasing prevalence of lung diseases, surge in geriatric population, and rising risk of pneumonia in children. According to the World Health Organization (WHO), respiratory syncytial virus (RSV) is responsible for around 30 million lower respiratory tract infection cases in children worldwide. The prevalence of such viral diseases is expected to drive growth of the global market over the forecast period.
Increasing air pollution can severely affect respiratory health of children as well as adults. Various studies have shown effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies.
However, adverse effects of using NSAIDs and antibiotics on patients suffering from respiratory tract infection may hinder growth of the market. In 2015, the U.S. Food and Drug Administration (FDA) increased the warning labels on over-the-counter NSAIDs to highlight elevated risks for heart attack and stroke.
Key features of the study:
- This report provides in-depth analysis of the respiratory tract infection treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global respiratory tract infection treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global respiratory tract infection treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for respiratory tract infection treatment market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Respiratory Tract Infection Treatment Market, By Drug Class:
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Cough Suppressant
- Nasal Decongestant
- Others
- Global Respiratory Tract Infection Treatment Market, By Disease Indication:
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- Global Respiratory Tract Infection Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Respiratory Tract Infection Treatment Market, By Region:
- North America
- By Country:
- By Drug Class:
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Cough Suppressant
- Nasal Decongestant
- Others
- By Disease Indication:
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Class:
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Cough Suppressant
- Nasal Decongestant
- Others
- By Disease Indication:
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Class:
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Cough Suppressant
- Nasal Decongestant
- Others
- By Disease Indication:
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class:
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Cough Suppressant
- Nasal Decongestant
- Others
- By Disease Indication:
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Class:
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Cough Suppressant
- Nasal Decongestant
- Others
- By Disease Indication:
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country:
- South Africa
- Central Africa
- North Africa
- By Drug Class:
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Cough Suppressant
- Nasal Decongestant
- Others
- By Disease Indication:
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Abbott Laboratories*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AstraZeneca, Plc
- Abbvie Inc.
- Boehringer Ingelheim GmbH
- Cipla Pharmaceutical Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Merck & Co.
- Novartis AG
- F. Hoffman La Roche Ltd
- Sanofi
- Teva Pharmaceutical Industries Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
